BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Par Pharmaceutical, Inc. Begins Shipment Of Generic Lanoxin®


1/17/2014 8:00:37 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WOODCLIFF LAKE, N.J.
, Jan. 16, 2014 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that it has entered into an exclusive U.S. supply and distribution agreement with Covis Pharma S.a.r.l. to distribute the authorized generic version of Covis's Lanoxin® (digoxin) Tablets. The Lanoxin® brand has been relied upon for its quality and availability for more than 50 years. Digoxin tablets are indicated for treatment of mild to moderate heart failure in adults; increasing myocardial contractility in pediatric patients with heart failure; and control of resting ventricular rate in patients with chronic atrial fibrillation in adults.

Par has begun shipping 0.125 mg and 0.25 mg strengths of digoxin tablets. According to IMS Health data, annual U.S. sales of digoxin tablets are approximately $44 million.

Important Information About Digoxin Tablets
Digoxin tablets are contraindicated in patients with ventricular fibrillation and in patients with a known hypersensitivity to digoxin (reactions seen include unexplained rash, swelling of the mouth, lips or throat or a difficulty in breathing). A hypersensitivity reaction to other digitalis preparations usually constitutes a contraindication to digoxin. For full prescribing information, please visit www.parpharm.com.

About Par Pharmaceutical Companies, Inc.
Par Pharmaceutical Companies, Inc. is a privately held, U.S.-based specialty pharmaceutical company that develops, manufactures and markets high barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals through its wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals. For press release and other company information, visit www.parpharm.com.

About Covis Pharma
Headquartered in Zug, Switzerland, Covis Pharma S.a.r.l. is a global specialty pharmaceutical company providing therapeutic solutions to patients. The company's distinctive product portfolio addresses life threatening and other serious medical conditions. For more information, visit www.covispharma.com.

SOURCE Par Pharmaceutical Companies, Inc.



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES